# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price ta...
Leerink Partners analyst Andrew Berens downgrades Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Market Perform and lo...